AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01029626 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopy
Description: Realization of an upper GI endoscopy
Study NCT03983291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FaReWell Depression
Description: Facial massage and force exercise
Study NCT03983291 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: FaReWell Depression
Description: Facial massage and force exercise
Study NCT00487773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Description: budesonide
Study NCT00487773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D3 vitamin
Description: D3 vitamin
Study NCT03614702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2-doses sIPV + 1-dose tOPV (Liquid)
Description: Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
Study NCT02550860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: soybean oil (SO)-based IVFE (Medialipide)
Description: The soybean oil (SO)-based IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
Study NCT00487773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast sodium
Description: montelukast sodium
Study NCT02550860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fish oil (FO)-containing IVFE (Lipidem)
Description: The fish oil (FO)-containing IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
Study NCT02587975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin
Description: 10 mg
Study NCT01339676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colecalciferol
Description: Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D
Study NCT01339676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Identically appearing once weekly peroral placebo capsules
Study NCT00673218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Q2 or 4 weeks depending on Ige level and weight as appropriate for active treatment.
Study NCT00673218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolair
Description: 150 to 375 mg is administered SC every 2 or 4 weeks
Study NCT00809614 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: The investigational drug, AIN457 50 mg lyophilizate vials was prepared by Novartis. Reconstitution of AIN457 with 1.2 mL SWFI produced a 47 mg/mL concentrate solution for infusion from which at least 1 mL was useable. The AIN457 concentrate was diluted in 5% glucose bags for infusion through a 0.2 micron in-line filter.
Study NCT00809614 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to AIN457
Study NCT02268760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILN 2061 ZW single rising doses
Study NCT02268760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02268760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BILN 2061 ZW fixed dose
Study NCT02268760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILN 2061 ZW fixed dose
Study NCT02268760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized breakfast
Study NCT04946760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Manipulation
Description: The sham protocol will consist of examination of the subject's active and passive range of motion in the spine and extremities, in the joints that would have been treated with OMT. The subject will be positioned in sitting, supine and lateral recumbent in a similar manner to that of the OMT group, but without providing an active intervention.
Study NCT04946760 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Manipulation
Description: The sham protocol will consist of examination of the subject's active and passive range of motion in the spine and extremities, in the joints that would have been treated with OMT. The subject will be positioned in sitting, supine and lateral recumbent in a similar manner to that of the OMT group, but without providing an active intervention.
Study NCT02144090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve measurement
Description: Fractional flow reserve measurement
Study NCT01731275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6011
Description: A single ascending dose (SAD) administration of E6011 is administered to 8 groups as a 30-minute intravenous infusion at a dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
Study NCT01731275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E6011 Matching Placebo
Description: A SAD administration of E6011 Matching Placebo is administered to 2 participants in each of 8 groups as a 30-minute intravenous infusion at a placebo dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending E6011 Matching Placebo dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
Study NCT01378676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Part A)
Description: Placebo tablets once daily for 14 days (Part A)
Study NCT01378676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part A)
Description: Placebo tablets once daily for 14 days (Part A)
Study NCT01378676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-2017357 (Part A)
Description: One 125 mg CK-2017357 tablet once daily for 14 days (Part A)
Study NCT01378676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-2017357 (Part A)
Description: Two 125 mg CK-2017357 tablets once daily for 14 days (Part A)
Study NCT01378676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-2017357 (Part A)
Description: Three 125 mg CK-2017357 tablets once daily for 14 days (Part A)
Study NCT01378676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole 50 MG (Part B)
Description: One 50 mg tablet once daily for 14 days (Part B)
Study NCT01378676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole 50 MG (Part B)
Description: One 50 mg tablet once daily for 14 days (Part B)
Study NCT01378676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Part B)
Description: Placebo tablets once daily for 14 days (Part B)
Study NCT01378676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part B)
Description: Placebo tablets once daily for 14 days (Part B)
Study NCT01378676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-2017357 (Part B)
Description: One 125 mg tablet once daily for 14 days (Part B)
Study NCT01378676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-2017357 (Part B)
Description: Two 125 mg tablets once daily for 14 days (Part B)
Study NCT01378676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-2017357 (Part B)
Description: Three 125 mg tablets once daily for 14 days (Part B)
Study NCT04770025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-density transcranial alternating current stimulation
Description: High-density electrode configuration with transcranial alternating current stimulation in the beta (15-40Hz) frequency range
Study NCT04770025 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: High-density electrode configuration with sham stimulation
Study NCT04770025 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Motivational interviewing
Description: Motivational interviewing session focused on alcohol use, approximately 30 minutes in length
Study NCT04770025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Motivational interviewing session focused on alcohol use, approximately 30 minutes in length
Study NCT04770025 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational interviewing
Description: Motivational interviewing session focused on alcohol use, approximately 30 minutes in length
Study NCT02462811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)
Study NCT02462811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02462811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)
Study NCT01922518 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Septal pacing
Description: Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis
Study NCT01922518 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apex pacing
Description: Put RV lead around the apex
Study NCT00877227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv)
Description: Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns.
Study NCT01281774 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL112
Description: reconstituted high density lipoprotein
Study NCT01281774 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9%)
Study NCT02311140 — intervention group
Intervention type: OTHER
Intervention: nasal lavage (routine diagnostic procedure in our centre), assessment of symptoms
Study NCT01153568 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D 3
Description: Patients will bew given a single capsule to take once daily
Study NCT01153568 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets
Study NCT01560754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine transdermal patch
Description: Transdermal patches containing 7 or 14 mg nicotine or placebo with subjects titrating up until reaching their highest tolerated dose of 7 to 28mg/day.
Study NCT01560754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nicotine transdermal patch
Description: Transdermal patches containing 7 or 14 mg nicotine or placebo with subjects titrating up until reaching their highest tolerated dose of 7 to 28mg/day.
Study NCT00088595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide (SOM230)
Description: Open label. Patients received starting dose of 300 µg of study drug subcutaneously (s.c.) twice (total of 600 µg ) daily for three days, which could be increased in 150 µg increments up to 900 µg twice daily (total 1800 µg daily) if control of symptoms was not achieved. Prior sponsor agreement was required for a higher dose. A dose of 2400 µg/day was the maximum allowed. Dose reductions of 300 µg/day were allowed at any time if unacceptable toxicity occurred.
Study NCT02982772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Intervention
Description: Brief Behavioral Intervention~The test product is transdermal Nicotine replacement patch for 10 weeks.The dosage of the test product follows the product guidelines and depends on the amount of cigarettes used.~Standard Flavored Gums for 10 weeks
Study NCT02686632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palatal brushing
Description: Brushing the palate as part of regular oral hygiene habits (behavior) among complete denture wearers.
Study NCT00822120 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00822120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABVD regimen
Study NCT04619238 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: King's Health Questionnaire
Description: patients fulfilled questionnaire
Study NCT04619238 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: the International Consultation on Incontinence Modular Questionnaire (ICIQ-SF) Short Form
Description: patients fulfilled ICIQ-SF questionnaire
Study NCT02222688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cirmtuzumab
Study NCT00040781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally
Study NCT00040781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT03739099 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions
Description: Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data
Study NCT03739099 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions
Description: Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data
Study NCT00040781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00822120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEACOPP regimen
Study NCT03927547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inclined Sleep
Description: Study participants randomized to the interventional arm will be instructed to sleep on inclined wedge mattress.
Study NCT03245554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 0 or 1 were generated by using Random software. The patient entered the placebo group if number was 0; if the random number generated was 1, then entered the propranolol group.
Study NCT00487773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salbutamol
Description: salbutamol
Study NCT02817191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylo-Comod eye drop
Description: The patients were administrated Hylo-Comod eye drop four times a day after Phaco+IOL
Study NCT02817191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tears Naturale Forte eye drop
Description: The patients were administrated Tears Naturale Forte eye drop four times a day after Phaco+IOL
Study NCT00822120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00482612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmirtazapine
Description: Esmirtazapine maleate was provided as tablets for oral use containing either 1.5, 3.0, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia \[USP\] name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
Study NCT00822120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine
Study NCT00482612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets containing the following excipients: hydroxypropyl cellulose, maize starch (USP name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
Study NCT03804047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio tape
Description: kinesio tape is a therapeutic method used in the treatment of various musculoskeletal and neuromuscular deficits to provide support for muscles and increase or inhibit muscle recruitment, to correct joint malalignment, decrease swelling, and pain relieve
Study NCT03804047 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: kinesio tape
Description: kinesio tape is a therapeutic method used in the treatment of various musculoskeletal and neuromuscular deficits to provide support for muscles and increase or inhibit muscle recruitment, to correct joint malalignment, decrease swelling, and pain relieve
Study NCT02380677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRLX301
Study NCT02414750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib plus cobimetinib
Description: Molecular targeted therapy for BRAF mutated advanced melanoma patients
Study NCT02414750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Patient will need to undergo FDG and FLT PET scanning before and during treatment, and at time of progression
Study NCT02414750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue sampling
Description: Before and during treatment and at time of progression patients will undergo tissue sampling of a melanoma lesion
Study NCT02414750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Before and during treatment and at time of progression patients will undergo blood sampling
Study NCT01837615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photopill treatment
Study NCT03841513 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Burch Colposuspension
Description: The Burch Colposuspension is an anti-incontinence procedure where non-absorbable monofilament suture is used in the retropubic space to form a suture bridge between the anterior vagina and Cooper's ligament, thereby gently elevating the anterior vaginal wall and providing urethral support.
Study NCT04381403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bio-descaling D-Tart toothpaste
Description: Patients received Bio-descaling D-Tart toothpaste, which is a new dentifrice (Visionaturolab Inc., QC) that contains a natural bio-descaler powder of cuttlefish bone
Study NCT04381403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crest® toothpaste
Description: Patients received Crest toothpaste; Anti-tartar toothpaste
Study NCT00822120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Study NCT00822120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00458198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated behavioral therapy (BT)
Description: Participants in the BT condition will receive twenty 60-minute sessions over 24 weeks. Sessions will focus on graduated exposure to new speaking situations as the primary agent of anxiety reduction. Behavioral procedures will include systematic desensitization, shaping, and self-modeling procedures. Although a variety of exposure exercises will be routinely conducted in-session, any behavioral assignments will take place outside of session. Behavioral exercises will be implemented, as needed, in a modular fashion. For example, exercises may focus on speaking in-session to therapist, either at school or at home with others present. The therapist will be primarily responsible for developing the exposure parameters, but collaboration of parent, teacher, child will be emphasized increasingly over time. Reinforcement for attempts to complete assignments (contingency management program) will occur throughout treatment.
Study NCT01530178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: In each intervention arm the participant receives a different dose of sitagliptin.
Study NCT00458198 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated behavioral therapy (BT)
Description: Participants in the BT condition will receive twenty 60-minute sessions over 24 weeks. Sessions will focus on graduated exposure to new speaking situations as the primary agent of anxiety reduction. Behavioral procedures will include systematic desensitization, shaping, and self-modeling procedures. Although a variety of exposure exercises will be routinely conducted in-session, any behavioral assignments will take place outside of session. Behavioral exercises will be implemented, as needed, in a modular fashion. For example, exercises may focus on speaking in-session to therapist, either at school or at home with others present. The therapist will be primarily responsible for developing the exposure parameters, but collaboration of parent, teacher, child will be emphasized increasingly over time. Reinforcement for attempts to complete assignments (contingency management program) will occur throughout treatment.